BMC women's health · 2025
Value of injection of plasma-rich platelets in the vaginal mucosa in cases with vulvovaginal atrophy: a prospective double-blinded randomized controlled study.
СтатьяМногоцентровое исследованиеРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hamid Ahmed Sherif Abdel, AbdAllah Aya Masoud, Fathi Hesham Mohamed, Eldin Ahmed Mohamed Bahaa, Abd El Hadi Rasha Mahmoud Medhat
Аннотация
OBJECTIVES: The use of Plasma-Rich Platelets (PRP) in the vaginal mucosa for vulvovaginal atrophy (VVA) symptom relief is still being studied. This trial aimed to assess the efficacy of PRP injections in alleviating VVA symptoms.
METHODS: A prospective randomized controlled trial was conducted at Ain Shams University Hospital, involving 60 postmenopausal women experiencing vaginal atrophy from August 2019 to May 2021. Thirty participants received intramucosal PRP injections, while the other 30 received saline as a placebo. Clinical evaluations occurred after 4 months using the Female Sexual Function Index (FSFI) as the primary outcome measure, alongside assessments of quality of life domains using the 36-item short-form survey (SF-36).The independent t-test and paired t-test were utilized for comparisons.
RESULTS: At baseline, both groups exhibited impaired FSFI scores (9.2 ± 4.2 vs. 9.8 ± 4.3, P > 0.05). After four months of treatment, the FSFI scores significantly improved in the PRP group (19.0 ± 4.5 vs. 9.7 ± 4.3, P < 0.001). Specific domain analysis revealed no significant differences before treatment (P > 0.05), but the PRP group showed significant improvements in lubrication (2.26 ± 0.99 vs. 1.15 ± 0.81, P = 0.02), satisfaction (5.27 ± 0.63 vs. 1.31 ± 0.78, P < 0.001), and pain (5.18 ± 0.59 vs. 2.51 ± 1.63, P < 0.001). No differences were seen in desire, arousal, and orgasm (P > 0.05). The PRP group also demonstrated notable improvements in role limitations due to physical health (52.5 ± 10.1 vs. 25.8 ± 12.3, P < 0.001), emotional problems (56.6 ± 15.5 vs. 24.4 ± 17.3, P < 0.001), and energy/fatigue (56.6 ± 15.5 vs. 24.4 ± 17.3, P < 0.001), among others, all significant at P < 0.001.
CONCLUSIONS: PRP injections show promise for treating postmenopausal VVA but require further larger RCT studies before becoming a standard treatment.
TRIAL REGISTRATION: The study was prospectively registered in the clinical trials registry (NCT03898401) on 19.3.2019, https//clinicaltrials.gov/study/NCT03898401.
METHODS: A prospective randomized controlled trial was conducted at Ain Shams University Hospital, involving 60 postmenopausal women experiencing vaginal atrophy from August 2019 to May 2021. Thirty participants received intramucosal PRP injections, while the other 30 received saline as a placebo. Clinical evaluations occurred after 4 months using the Female Sexual Function Index (FSFI) as the primary outcome measure, alongside assessments of quality of life domains using the 36-item short-form survey (SF-36).The independent t-test and paired t-test were utilized for comparisons.
RESULTS: At baseline, both groups exhibited impaired FSFI scores (9.2 ± 4.2 vs. 9.8 ± 4.3, P > 0.05). After four months of treatment, the FSFI scores significantly improved in the PRP group (19.0 ± 4.5 vs. 9.7 ± 4.3, P < 0.001). Specific domain analysis revealed no significant differences before treatment (P > 0.05), but the PRP group showed significant improvements in lubrication (2.26 ± 0.99 vs. 1.15 ± 0.81, P = 0.02), satisfaction (5.27 ± 0.63 vs. 1.31 ± 0.78, P < 0.001), and pain (5.18 ± 0.59 vs. 2.51 ± 1.63, P < 0.001). No differences were seen in desire, arousal, and orgasm (P > 0.05). The PRP group also demonstrated notable improvements in role limitations due to physical health (52.5 ± 10.1 vs. 25.8 ± 12.3, P < 0.001), emotional problems (56.6 ± 15.5 vs. 24.4 ± 17.3, P < 0.001), and energy/fatigue (56.6 ± 15.5 vs. 24.4 ± 17.3, P < 0.001), among others, all significant at P < 0.001.
CONCLUSIONS: PRP injections show promise for treating postmenopausal VVA but require further larger RCT studies before becoming a standard treatment.
TRIAL REGISTRATION: The study was prospectively registered in the clinical trials registry (NCT03898401) on 19.3.2019, https//clinicaltrials.gov/study/NCT03898401.